Dr Oleg Gluz speaks to ecancer about the multicenter ADAPTcycle trial. This study investigated the impact of age and ovarian function suppression (OFS) on endocrine response to short-preoperative endocrine therapy (ET).

ADAPTcycle confirms ADAPT ET-response rates in patients receiving tamoxifen or aromatase inhibitors; adding OFS improves ET-response, irrespective of recurrence score. Endocrine therapy response measurement adds value to therapy decisions, particularly in 50-year-old or above patients.

The study found that optimal preoperative ET, especially in premenopausal patients, might even enable sparing chemotherapy in additional patients.